Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design
- PMID: 22386481
- PMCID: PMC5528372
- DOI: 10.1016/j.molonc.2012.01.009
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design
Abstract
With the event of new Molecular targets, clinical trial design requirements to perform these trials are changing. This paper discusses some of the considerations that need to be taken into account when designing a trial, including those trials that assess combinations of targets.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
References
-
- de Bono, J. , Ashworth, A. , 2010. Translating cancer research into targeted therapeutics. Nature. 467, 543549 - PubMed
-
- Chabner, B. , 2011. Early accelerated approval for highly targeted drugs. N. Engl. J. Med.. 364, 1087–1089. - PubMed
-
- Eisenhauer, E. , Therasse, P. , Bogaerts, J. , 2009. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228–247. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
